CEO says Lilly against push to pass drug pricing deals into law, CNBC reports

Eli Lilly (LLY) opposes the White House’s push to codify “most favored nation” drug pricing into law, CEO Dave Ricks said in an interview with CNBC. Lilly is one of more than a dozen drugmakers that signed deals with the Trump administration last year agreeing to charge similar prices for prescription drugs in the U.S. as other wealthy nations, CNBC’s Angelica Peebles notes. “When you throw it into the congressional process, what goes in is not what’s going to come out,” Ricks said. Ricks said he thinks the Trump administration and leadership on the Hill are listening to the company’s concerns, but he said Lilly will use “all the tools we have to combat bad policy, and we think it would be bad policy.”